Scientific Advisory Board

Solving Kids’ Cancer’s Scientific Advisory Board (SAB) has responsibility for providing expert advice, guidance, and input with regards to the charity’s research strategy, and for overseeing the development of a formal, structured, scientifically robust, and accredited grant award process.

The SAB has been established to strengthen our focus on how we can best drive clinical research forward, with a view to achieving better outcomes for children with neuroblastoma. It will be involved in advising SKC on clinical and scientific matters, helping us to link closer with the wider neuroblastoma research and clinical community. This will enable us to ensure we are investing in the most cutting-edge research to increase the UK’s clinical trial footprint, allowing more children to access innovative therapies closer to home. This is an urgent and vital need, as neuroblastoma remains one of the leading causes of death from cancer in children.

As per our Strategic Plan, Solving Kids’ Cancer is committed to proactively driving forward the development of more effective and less toxic therapies to improve survival and cure rates, whilst reducing the cost of cure in terms of treatment-related health problems. We aim to play a leading role in increasing, shaping, and accelerating neuroblastoma research in the UK; bringing insight from those impacted by neuroblastoma and working in partnership with researchers, clinicians, and charity partners.

The neuroblastoma research landscape is global in nature and we have a fundamental belief at Solving Kids’ Cancer that investment in, and access to, the most innovative and promising new therapies should not be constrained by geography. Moreover, in today’s interconnected world where access to genomic information is identifying smaller sub-groups of patients, collaborative research efforts are becoming increasingly more important. Reflecting this, our Scientific Advisory Board is deliberately international in composition, comprising leading experts in neuroblastoma from the UK, Europe and America.


Our SAB is comprised of eminent researchers from the UK, Europe and the US; most of whom have dedicated their lives to achieving better outcomes for children with neuroblastoma. The current members of our SAB are:

Prof Andy Pearson (formerly of the Institute of Cancer Research and Royal Marsden Hospital)
Dr John Maris (Children’s Hospital of Philadelphia)
Dr Juliet Gray (University of Southampton)
Dr Lucas Moreno (Hospital Niño Jesús, Madrid)
Dr Julie Park (Seattle Children’s Hospital)
Dr Steven DuBois (Dana-Farber/Boston Children’s Cancer and Blood Disorders Center)
Prof Michel Zwaan (Erasmus MC, Rotterdam)

With their help and guidance we have developed a clearly defined Research Strategy; and a formal, structured and soon to be accredited research funding award process. The SAB members are not remunerated for their role, and we are extremely grateful to them for all the time they have dedicated to supporting us in achieving our joint goals of improving outcomes for children with neuroblastoma.